 <h1>Ninlaro Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>ixazomib</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about ixazomib. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Ninlaro.</p><h2>In Summary</h2><p><b>Common side effects of Ninlaro include:</b> constipation, diarrhea, macular eruption, maculopapular rash, nausea, peripheral edema, peripheral neuropathy, peripheral sensory neuropathy, skin rash, and vomiting. <b>Other side effects include:</b> hepatic insufficiency.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ixazomib: oral capsule</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ixazomib (the active ingredient contained in Ninlaro) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking ixazomib:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>black, tarry stools</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>chills</li>
<li>cough</li>
<li>dark urine</li>
<li>diarrhea</li>
<li>dizziness</li>
<li>fever</li>
<li>headache</li>
<li>itching or rash</li>
<li>light-colored stools</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>nausea</li>
<li>numbness, tingling, or pain in the hands or feet</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>rapid weight gain</li>
<li>rash with flat lesions or small raised lesions on the skin</li>
<li>redness or discoloration of the skin</li>
<li>sore throat</li>
<li>tingling of the hands or feet</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unpleasant breath odor</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
<li>vomiting of blood</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bleeding gums</li>
<li>blood in the urine or stools</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>bloody nose</li>
<li>heavier menstrual periods</li>
<li>joint or muscle pain</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ixazomib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>blurred vision</li>
<li>body aches or pain</li>
<li>burning, dry, or itching eyes</li>
<li>difficulty having a bowel movement (stool)</li>
<li>discharge, excessive tearing</li>
<li>ear congestion</li>
<li>loss of voice</li>
<li>nasal congestion</li>
<li>redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid</li>
<li>sneezing</li>
</ul><p>
<!-- end oral capsule --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ixazomib: oral capsule</i></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Peripheral edema (18%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (11%)</p>
<p><b>Postmarketing reports</b>: Acute febrile neutrophilic dermatosis (Sweet's syndrome), Stevens-Johnson syndrome<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (36%), constipation (25%), nausea (21%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Thrombocytopenia (78%), neutropenia (67%), thrombotic thrombocytopenic purpura<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Hepatotoxicity<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Postmarketing reports</b>: Transverse myelitis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Postmarketing reports</b>: Tumor lysis syndrome<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (16%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Frequency not reported</b>: Peripheral neuropathy (21%)</p>
<p><b>Postmarketing reports</b>: Posterior reversible encephalopathy syndrome<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Blurred vision, dry eye, conjunctivitis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (14%)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America, Lincolnshire, IL. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>How much does Ninlaro cost compared to other chemo drugs?</li>
<li>What is Ninlaro used for?</li>
<li>Ninlaro vs Velcade, which is better?</li>
<li>Is Ninlaro (ixazomib) a chemotherapy drug? How does it work?</li>
<li>Does Ninlaro cause shingles (herpes zoster)?</li>
<li>How effective is Ninlaro (ixazomib)?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Ninlaro (ixazomib)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>3 Reviews</li>
<li>Drug class: proteasome inhibitors</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ninlaro &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Multiple Myeloma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ixazomib: oral capsule</i></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Peripheral edema (18%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (11%)</p><p><b>Postmarketing reports</b>: Acute febrile neutrophilic dermatosis (Sweet's syndrome), Stevens-Johnson syndrome<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (36%), constipation (25%), nausea (21%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Thrombocytopenia (78%), neutropenia (67%), thrombotic thrombocytopenic purpura<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Hepatotoxicity<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Postmarketing reports</b>: Transverse myelitis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Postmarketing reports</b>: Tumor lysis syndrome<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (16%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Frequency not reported</b>: Peripheral neuropathy (21%)</p><p><b>Postmarketing reports</b>: Posterior reversible encephalopathy syndrome<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Blurred vision, dry eye, conjunctivitis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (14%)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America, Lincolnshire, IL. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>How much does Ninlaro cost compared to other chemo drugs?</li>
<li>What is Ninlaro used for?</li>
<li>Ninlaro vs Velcade, which is better?</li>
<li>Is Ninlaro (ixazomib) a chemotherapy drug? How does it work?</li>
<li>Does Ninlaro cause shingles (herpes zoster)?</li>
<li>How effective is Ninlaro (ixazomib)?</li>
</ul><h2>More about Ninlaro (ixazomib)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>3 Reviews</li>
<li>Drug class: proteasome inhibitors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ninlaro &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Multiple Myeloma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>